

Adjuvant Treatment of Colorectal Cancer

Ca-A Cancer Journal for Clinicians

57, 168-185

DOI: [10.3322/canjclin.57.3.168](https://doi.org/10.3322/canjclin.57.3.168)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Update in colorectal, hepatobiliary and pancreatic cancers. Update on Cancer Therapeutics, 2007, 2, 141-156.	0.9	0
2	Pain, Pulmonary Function, and Early Recovery After Minimally Invasive Surgery. Seminars in Colon and Rectal Surgery, 2007, 18, 205-209.	0.2	0
3	The use of molecular markers in the diagnosis and treatment of colorectal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 1071-1087.	1.0	17
4	Decreased Expression of Monocyte Chemoattractant Protein-1 Predicts Poor Prognosis Following Curative Resection of Colorectal Cancer. Diseases of the Colon and Rectum, 2008, 51, 1800-1805.	0.7	13
5	Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. British Journal of Cancer, 2008, 98, 450-456.	2.9	67
6	Î²2microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients. British Journal of Cancer, 2008, 98, 1999-2005.	2.9	27
7	HOST RESPONSE TO COLORECTAL CANCER. ANZ Journal of Surgery, 2008, 78, 745-753.	0.3	19
8	Orthotopic implantation mouse model and cDNA microarray analysis indicates several genes potentially involved in lymph node metastasis of colorectal cancer. Cancer Science, 2008, 99, 711-719.	1.7	42
9	Ganoderma tsugae extracts inhibit colorectal cancer cell growth via G2/M cell cycle arrest. Journal of Ethnopharmacology, 2008, 120, 394-401.	2.0	58
10	The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. NeuroToxicology, 2008, 29, 1100-1106.	1.4	91
11	Recent trends in cancer survival across Europe between 2000 and 2004: A model-based period analysis from 12 cancer registries. European Journal of Cancer, 2008, 44, 1463-1475.	1.3	101
12	The impact of T and N stage on long-term survival of rectal cancer patients in the community. Journal of Surgical Oncology, 2008, 98, 161-166.	0.8	20
13	Prognostic Relevance of Occult Nodal Micrometastases and Circulating Tumor Cells in Colorectal Cancer in a Prospective Multicenter Trial. Clinical Cancer Research, 2008, 14, 7391-7396.	3.2	101
14	Epithelial Human Leukocyte Antigen-DR Expression Predicts Reduced Recurrence Rates and Prolonged Survival in Rectal Cancer Patients. Clinical Cancer Research, 2008, 14, 1073-1079.	3.2	23
15	Local Recurrence in Mismatch Repair-Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes. Clinical Cancer Research, 2008, 14, 3792-3797.	3.2	44
16	Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer. Expert Opinion on Therapeutic Targets, 2008, 12, 367-376.	1.5	29
17	Therapeutic burden in cancer revealed by molecular staging. Biomarkers in Medicine, 2008, 2, 1-3.	0.6	1
18	Adjuvant Chemotherapy Uptake in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1272-1278.	0.5	38

#	ARTICLE	IF	CITATIONS
19	Colorectal Conquering. Nursing Made Incredibly Easy, 2008, 6, 42-52.	0.2	0
20	Colorectal Adenocarcinoma Presenting as Abdominal Wall Cellulitis. Radiology Case Reports, 2008, 3, 204.	0.2	3
21	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 1024-1029.	0.4	1
22	Epithelial Neoplasms of the Large Intestine. , 2009, , 597-637.		7
23	GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Review of Molecular Diagnostics, 2009, 9, 777-785.	1.5	11
24	Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803. Journal of Clinical Oncology, 2009, 27, 1814-1821.	0.8	333
25	Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Annals of Oncology, 2009, 20, 564-573.	0.6	97
26	Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer. JAMA - Journal of the American Medical Association, 2009, 301, 745.	3.8	102
27	Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?. Genetics in Medicine, 2009, 11, 15-20.	1.1	110
28	Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biology and Therapy, 2009, 8, 1831-1837.	1.5	35
29	Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genetics in Medicine, 2009, 11, 21-34.	1.1	135
30	Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncologica, 2009, 48, 368-376.	0.8	54
31	Metastatic rectal cancer to the breast. Rare Tumors, 2009, 1, e22.	0.3	12
32	Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 176-185.	0.8	208
33	Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Prostaglandins and Other Lipid Mediators, 2009, 89, 140-146.	1.0	51
34	The effect of socioeconomic status on survival from colorectal cancer in the Melbourne Collaborative Cohort Study. Social Science and Medicine, 2009, 68, 290-297.	1.8	38
35	Factors associated with improved survival among older colorectal cancer patients in the US: a population-based analysis. BMC Cancer, 2009, 9, 227.	1.1	35
37	Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. European Journal of Pharmacology, 2009, 619, 8-14.	1.7	35

#	ARTICLE	IF	CITATIONS
38	Protein expression following $\hat{1}^3$ -irradiation relevant to growth arrest and apoptosis in colon cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1583-1592.	1.2	18
39	Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients. <i>International Journal of Colorectal Disease</i> , 2009, 24, 269-274.	1.0	19
40	Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone. <i>International Journal of Colorectal Disease</i> , 2009, 24, 655-663.	1.0	16
41	Neoadjuvant therapy for advanced rectal carcinoma in China: Whether radiochemotherapy is superior to radiotherapy?. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2009, 21, 295-303.	0.7	0
42	Matrix metalloproteinaseâ€2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer. <i>Cancer Science</i> , 2009, 100, 852-858.	1.7	9
43	Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. <i>Acta Pharmacologica Sinica</i> , 2009, 30, 1537-1542.	2.8	60
44	Extramural vascular invasion is an adverse prognostic indicator of survival in patients with colorectal cancer. <i>Colorectal Disease</i> , 2009, 11, 150-156.	0.7	39
45	Improving patient survival with the colorectal cancer multiâ€disciplinary team. <i>Colorectal Disease</i> , 2009, 11, 291-295.	0.7	170
46	Effect of Age on Survival Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 1403-1410.	1.3	59
47	Comparative proteomic analysis of colon cancer cells in response to Oxaliplatin treatment. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2009, 1794, 1433-1440.	1.1	27
48	Identification of High-Risk Stage II Colorectal Tumors by Combined Analysis of the NDRG1 Gene Expression and the Depth of Tumor Invasion. <i>Annals of Surgical Oncology</i> , 2009, 16, 1287-1294.	0.7	50
49	In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. <i>Nitric Oxide - Biology and Chemistry</i> , 2009, 20, 182-194.	1.2	49
50	The Multidisciplinary Management of Rectal Cancer. <i>Surgical Clinics of North America</i> , 2009, 89, 177-215.	0.5	34
51	Radiation Lobectomyâ€”A Minimally Invasive Treatment Model for Liver Cancer: Case Report. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 664-669.	0.2	25
52	Neoadjuvant Concurrent Chemoradiotherapy in Treating Locally Advanced Rectal Cancer. <i>Journal of the Chinese Medical Association</i> , 2009, 72, 179-182.	0.6	2
53	CD3+ cells at the invasive margin of deeply invading (pT3â€T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. <i>Lancet Oncology, The</i> , 2009, 10, 877-884.	5.1	226
54	Preoperative Serum Vascular Endothelial Growth Factor-A Is a Marker for Subsequent Recurrence in Colorectal Cancer Patients. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 993-999.	0.7	13
55	Combined Histomorphologic and Immunohistochemical Phenotype to Predict the Presence of Vascular Invasion in Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1114-1121.	0.7	12

#	ARTICLE	IF	CITATIONS
56	Suppression of N-Myc Downstream-Regulated Gene 2 Is Associated with Induction of Myc in Colorectal Cancer and Correlates Closely with Differentiation. <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 968-975.	0.6	30
57	Surgical Complications Are Associated With Omission of Chemotherapy for Stage III Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 1587-1593.	0.7	103
58	Bacterial Heat-Stable Enterotoxins: Translation of Pathogenic Peptides into Novel Targeted Diagnostics and Therapeutics. <i>Toxins</i> , 2010, 2, 2028-2054.	1.5	29
59	Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 659-667.	1.1	73
60	Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. <i>Clinical and Translational Oncology</i> , 2010, 12, 142-147.	1.2	23
61	Prognostic Factors in Patients With Colorectal Cancer at Hospital Universiti Sains Malaysia. <i>Asian Journal of Surgery</i> , 2010, 33, 127-133.	0.2	29
62	Identification of transgelin α 2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis. <i>Cancer Science</i> , 2010, 101, 523-529.	1.7	94
63	High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. <i>British Journal of Cancer</i> , 2010, 102, 908-915.	2.9	205
64	How useful is rectal endosonography in the staging of rectal cancer?. <i>World Journal of Gastroenterology</i> , 2010, 16, 691.	1.4	51
65	Expression of the Tumor Suppressor Kr μ 4ppel-Like Factor 4 as a Prognostic Predictor for Colon Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2631-2638.	1.1	62
66	Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006. <i>Annals of Oncology</i> , 2010, 21, 2206-2212.	0.6	98
67	Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF κ B and microRNA network. <i>Molecular Cancer</i> , 2010, 9, 98.	7.9	52
68	Molecular Staging Estimates Occult Tumor Burden in Colorectal Cancer. <i>Advances in Clinical Chemistry</i> , 2010, 52, 19-39.	1.8	4
69	Therapeutic efficacy and microSPECT/CT imaging of ¹⁸⁸ Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model. <i>Nuclear Medicine and Biology</i> , 2010, 37, 95-104.	0.3	75
70	Reversible stiff person syndrome presenting as an initial symptom in a patient with colon adenocarcinoma. <i>Acta Oncolαgica</i> , 2010, 49, 271-272.	0.8	15
71	Eudragit $\text{\textcircled{R}}$ S100 coated calcium pectinate microspheres of curcumin for colon targeting. <i>Journal of Microencapsulation</i> , 2011, 28, 659-667.	1.2	37
72	A Preliminary Evaluation of Multi-probe Resonance-frequency Electrical Impedance Based Measurements of the Breast. <i>Academic Radiology</i> , 2011, 18, 220-229.	1.3	12
73	The current landscape of locally advanced rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 649-659.	12.5	76

#	ARTICLE	IF	CITATIONS
74	Cancer stem cell-related factors are associated with the efficacy of pre-operative chemoradiotherapy for locally advanced rectal cancer. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 465-470.	0.8	6
75	Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?. <i>Clinical Colorectal Cancer</i> , 2011, 10, 73-80.	1.0	72
76	Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients. <i>Cancer Growth and Metastasis</i> , 2011, 4, CGM.S7113.	3.5	3
77	Distance to the closest radiotherapy facility and survival after a diagnosis of rectal cancer in Queensland. <i>Medical Journal of Australia</i> , 2011, 195, 350-354.	0.8	96
78	Matrix Metalloproteinase-2 and -7 Expression in Colorectal Cancer. <i>Journal of the Korean Society of Coloproctology</i> , 2011, 27, 133.	0.9	21
79	Comparative Effectiveness of Different Chemotherapeutic Regimens on Survival of People Aged 66 and Older with Stage III Colon Cancer: A "Real World" Analysis Using Surveillance, Epidemiology, and End Results "Medicare Data. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1717-1723.	1.3	19
80	Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus. <i>Cancer Gene Therapy</i> , 2011, 18, 336-345.	2.2	11
81	Expression of p21WAF1 in Astler "Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 431-438.	1.4	5
82	Study of sensitivity of different chemotherapeutic agents on colon cancer cell line SW480. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 266-269.	0.1	0
83	Deletion of chromosome 4q predicts outcome in Stage II colon cancer patients. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 215-223.	2.1	30
84	BAP31 is frequently overexpressed in patients with primary colorectal cancer and correlates with better prognosis. <i>Science Bulletin</i> , 2011, 56, 2444-2449.	1.7	7
85	Identification of high-risk stage II and stage III colorectal cancer by analysis of MMP-21 expression. <i>Journal of Surgical Oncology</i> , 2011, 104, 787-791.	0.8	16
86	Predicting Survival After Curative Colectomy for Cancer: Individualizing Colon Cancer Staging. <i>Journal of Clinical Oncology</i> , 2011, 29, 4796-4802.	0.8	150
87	Tailoring of drug delivery of 5-fluorouracil to the colon via a mixed film coated unit system. <i>Acta Pharmaceutica</i> , 2011, 61, 343-351.	0.9	1
88	Prediction of Colorectal Cancer Relapse and Prognosis by Tissue mRNA Levels of NDRG2. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 47-56.	1.9	38
89	Lymph Node Evaluation in Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1139.	3.8	25
90	Notch1 Expression, Which Is Related to p65 Status, Is an Independent Predictor of Prognosis in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5686-5694.	3.2	25
91	Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. <i>Annals of Oncology</i> , 2011, 22, 2440-2447.	0.6	81

#	ARTICLE	IF	CITATIONS
92	The Potential Use of N-Myristoyltransferase as a Biomarker in the Early Diagnosis of Colon Cancer. <i>Cancers</i> , 2011, 3, 1372-1382.	1.7	7
93	Occult Tumor Burden Predicts Disease Recurrence in Lymph Node-“Negative Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3293-3303.	3.2	28
94	Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer. <i>Chemotherapy Research and Practice</i> , 2012, 2012, 1-15.	1.6	3
95	GUCY2C molecular staging personalizes colorectal cancer patient management. <i>Biomarkers in Medicine</i> , 2012, 6, 339-348.	0.6	3
96	Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. <i>Oncology Reports</i> , 2012, 27, 1849-56.	1.2	55
97	Postoperative adjuvant chemotherapy in rectal cancer operated for cure.. <i>The Cochrane Library</i> , 2012, , CD004078.	1.5	156
98	An Interactive System for Computer-Aided Diagnosis of Breast Masses. <i>Journal of Digital Imaging</i> , 2012, 25, 570-579.	1.6	17
99	Improvement in T-Staging of Rectal Carcinoma: Using a Novel-Endorectal Ultrasonography Technique with Sterile-Coupling Gel Filling the Rectum. <i>Ultrasound in Medicine and Biology</i> , 2012, 38, 574-579.	0.7	10
100	How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study. <i>Implementation Science</i> , 2012, 7, 102.	2.5	2
102	Multidisciplinary Management of Rectal Cancer. , 2012, , .		5
103	Computational Analysis of mRNA Expression Profiles Identifies MicroRNA-29a/c as Predictor of Colorectal Cancer Early Recurrence. <i>PLoS ONE</i> , 2012, 7, e31587.	1.1	68
104	NMT1 (N-myristoyltransferase 1). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2012, 15, 570-575.	0.1	6
105	Distinct Pathologic Roles for Glycogen Synthase Kinase 3 ^β in Colorectal Cancer Progression. , 2012, , .		2
106	Comparative Effectiveness of Adjuvant Chemotherapy in Elderly Colon Cancer Patients. <i>Cancer and Clinical Oncology</i> , 2012, 2, .	0.2	0
107	A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. <i>Journal of Cancer</i> , 2012, 3, 231-240.	1.2	50
108	Matrix Metalloproteinase-9 Is Associated with Relapse and Prognosis of Patients with Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 318-325.	0.7	49
109	Molecular staging individualizing cancer management. <i>Journal of Surgical Oncology</i> , 2012, 105, 468-474.	0.8	18
110	Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: The EURO CARE study. <i>International Journal of Cancer</i> , 2012, 131, 1649-1658.	2.3	216

#	ARTICLE	IF	CITATIONS
111	Visinin-like protein-1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients. <i>International Journal of Cancer</i> , 2012, 131, 1307-1317.	2.3	15
112	Shifting concepts in rectal cancer management. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 173-202.	157.7	90
113	A possible link of oxaliplatin-induced neuropathy with potassium channel deficit. <i>Muscle and Nerve</i> , 2012, 45, 403-411.	1.0	21
114	Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. <i>BMC Gastroenterology</i> , 2013, 13, 36.	0.8	50
115	EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer. <i>Medical Oncology</i> , 2013, 30, 369.	1.2	25
116	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. <i>Clinical Colorectal Cancer</i> , 2013, 12, 233-238.	1.0	31
117	Molecular Diagnostics in Colorectal Carcinoma. <i>Clinics in Laboratory Medicine</i> , 2013, 33, 835-859.	0.7	19
118	Assessing the permeability of the rat sciatic nerve epineural sheath against compounds with local anesthetic activity: an <i>ex vivo</i> electrophysiological study. <i>Toxicology Mechanisms and Methods</i> , 2013, 23, 634-640.	1.3	3
119	Abdominal Lymph Node Anatomy. , 2013, , 59-88.		1
120	Quercetin Liposome Sensitizes Colon Carcinoma to Thermo-therapy and Thermochemotherapy in Mice Models. <i>Integrative Cancer Therapies</i> , 2013, 12, 264-270.	0.8	25
121	Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model. <i>Investigational New Drugs</i> , 2013, 31, 801-811.	1.2	14
122	RhoE is Associated with Relapse and Prognosis of Patients with Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 175-182.	0.7	19
123	Radiotherapy Response in Microsatellite Instability Related Rectal Cancer. <i>Korean Journal of Pathology</i> , 2013, 47, 1.	1.2	31
124	The Effects of Hyperbaric Oxygen Therapy on Experimental Colon Anastomosis After Preoperative Chemoradiotherapy. <i>International Surgery</i> , 2013, 98, 33-42.	0.0	8
125	Intermediate-Fraction Neoadjuvant Radiotherapy for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 422-432.	0.7	17
126	Colorectal Cancer Biomarkers and the Potential Role of Cancer Stem Cells. <i>Journal of Cancer</i> , 2013, 4, 241-250.	1.2	67
127	MicroRNA-630 is a prognostic marker for patients with colorectal cancer. <i>Tumor Biology</i> , 2014, 35, 9787-9792.	0.8	27
128	Combined therapeutic efficacy of 188Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26-luc murine colon cancer cells. <i>Molecular and Clinical Oncology</i> , 2014, 2, 380-384.	0.4	14

#	ARTICLE	IF	CITATIONS
129	The impact of cell proliferation markers and p53 mutation status on prognosis of non-metastatic colon cancer. <i>Journal of Surgical Oncology</i> , 2014, 109, 665-675.	0.8	4
130	The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy. <i>European Journal of Cancer Care</i> , 2014, 23, 394-400.	0.7	18
131	High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients. <i>BMC Cancer</i> , 2014, 14, 951.	1.1	108
132	The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis. <i>Medical Oncology</i> , 2014, 31, 781.	1.2	37
133	Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 179-188.	0.7	38
134	Predictive markers of radiotherapy-induced rectal cancer regression. <i>Journal of Clinical Pathology</i> , 2014, 67, 859-864.	1.0	15
135	Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients. <i>Tumor Biology</i> , 2014, 35, 3569-3574.	0.8	12
136	The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study. <i>BMJ Open</i> , 2014, 4, e005012-e005012.	0.8	17
137	Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients. <i>BioScience Trends</i> , 2015, 9, 393-401.	1.1	38
138	Ginsenoside Rg3 inhibits colon cancer cell migration by suppressing nuclear factor kappa B activity. <i>Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine</i> , 2015, 35, 440-444.	0.4	29
139	Combined assays for serum carcinoembryonic antigen and microRNA-17-3p offer improved diagnostic potential for stage I/II colon cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1315-1318.	0.4	20
140	The anticancer effect of Huaier (Review). <i>Oncology Reports</i> , 2015, 34, 12-21.	1.2	63
141	Dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. <i>Cancer Letters</i> , 2015, 357, 582-590.	3.2	44
142	Prognostic value of HLA class I expression in patients with colorectal cancer. <i>World Journal of Surgical Oncology</i> , 2015, 13, 36.	0.8	19
143	Overexpression of Wnt7 \pm protein predicts poor survival in patients with colorectal carcinoma. <i>Tumor Biology</i> , 2015, 36, 8781-8787.	0.8	6
144	Colorectal Cancer Survivorship Management. , 2015, , 71-93.		0
145	Clinical features and prognosis in hepatectomy for colorectal cancer with centrally located liver metastasis. <i>World Journal of Surgical Oncology</i> , 2015, 13, 92.	0.8	26
146	Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. <i>Proteomics - Clinical Applications</i> , 2015, 9, 1078-1086.	0.8	7

#	ARTICLE	IF	CITATIONS
147	Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. <i>International Journal of Cancer</i> , 2015, 137, 212-220.	2.3	94
148	The Evaluation of More Lymph Nodes in Colon Cancer Is Associated with Improved Survival in Patients of All Ages. <i>PLoS ONE</i> , 2016, 11, e0155608.	1.1	8
149	Decision-making by surgeons about referral for adjuvant therapy for patients with non-small-cell lung, breast or colorectal cancer: a qualitative study. <i>CMAJ Open</i> , 2016, 4, E7-E12.	1.1	5
150	Current Controversies in Transanal Surgery for Rectal Cancer. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2016, 26, 431-438.	0.4	6
151	The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis. <i>BMC Cancer</i> , 2016, 16, 249.	1.1	39
152	Loss of APAF-1 expression is associated with early recurrence in stage I, II, and III colorectal cancer. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 1203-1210.	0.8	5
153	Epigenome-wide analysis of DNA methylation reveals a rectal cancer-specific epigenomic signature. <i>Epigenomics</i> , 2016, 8, 1193-1207.	1.0	22
154	E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy. <i>Pathology and Oncology Research</i> , 2016, 22, 601-608.	0.9	12
155	Erectile and urinary function in men with rectal cancer treated by neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy alone: a randomized trial report. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1349-1357.	1.0	22
156	Geographic Variation in Oxaliplatin Chemotherapy and Survival in Patients With Colon Cancer. <i>American Journal of Therapeutics</i> , 2016, 23, e720-e729.	0.5	11
157	CDX2: Linking Cell and Patient Fates in Colon Cancer. <i>Cell Stem Cell</i> , 2016, 18, 168-169.	5.2	4
158	Ribosomal protein S15A promotes malignant transformation and predicts poor outcome in colorectal cancer through misregulation of p53 signaling pathway. <i>International Journal of Oncology</i> , 2016, 48, 1628-1638.	1.4	32
159	XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1663-1673.	3.2	43
160	Opposing prognostic roles of nuclear and cytoplasmic RACGAP1 expression in colorectal cancer patients. <i>Human Pathology</i> , 2016, 47, 45-51.	1.1	15
161	Patterns of computed tomography surveillance in survivors of colorectal cancer at Veterans Health Administration facilities. <i>Cancer</i> , 2017, 123, 2338-2351.	2.0	8
162	Overexpression of long non-coding RNA colon cancer-associated transcript 2 is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer. <i>Oncology Letters</i> , 2017, 14, 6907-6914.	0.8	21
163	Use of a Combination of CEA and Tumor Budding to Identify High-risk Patients with Stage II Colon Cancer. <i>International Journal of Biological Markers</i> , 2017, 32, 267-273.	0.7	7
164	CDK1 interacts with iASPP to regulate colorectal cancer cell proliferation through p53 pathway. <i>Oncotarget</i> , 2017, 8, 71618-71629.	0.8	30

#	ARTICLE	IF	CITATIONS
165	Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study. <i>Medical Science Monitor</i> , 2018, 24, 1970-1979.	0.5	3
166	High expression of ALDOA and DDX5 are associated with poor prognosis in human colorectal cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 1799-1806.	0.9	31
167	Long noncoding RNA SNHG14 facilitates colorectal cancer metastasis through targeting EZH2-regulated EPHA7. <i>Cell Death and Disease</i> , 2019, 10, 514.	2.7	87
168	Functional Prediction of Candidate MicroRNAs for CRC Management Using in Silico Approach. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5190.	1.8	6
169	Liquid biopsy for rectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2019, 79, 101893.	3.4	28
170	Long Non-coding RNA ITIH4-AS1 Accelerates the Proliferation and Metastasis of Colorectal Cancer by Activating JAK/STAT3 Signaling. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 183-193.	2.3	43
171	Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome. <i>FASEB BioAdvances</i> , 2019, 1, 723-730.	1.3	7
172	A novel nanoparticle-based theranostic agent targeting LRP-1 enhances the efficacy of neoadjuvant radiotherapy in colorectal cancer. <i>Biomaterials</i> , 2020, 255, 120151.	5.7	27
173	Serum miR-92a-1 is a novel diagnostic biomarker for colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 8363-8367.	1.6	18
174	Recruitment strategies and design considerations in a trial of resistance training to prevent dose-limiting toxicities in colon cancer patients undergoing chemotherapy. <i>Contemporary Clinical Trials</i> , 2021, 101, 106242.	0.8	13
175	Abdominal Lymph Node Anatomy. , 2021, , 55-91.		0
176	USP43 directly regulates ZEB1 protein, mediating proliferation and metastasis of colorectal cancer. <i>Journal of Cancer</i> , 2021, 12, 404-416.	1.2	18
177	The effect of mutation status, pathological features and tumor location on prognosis in patients with colorectal cancer. <i>Revista Da Associação Médica Brasileira</i> , 2021, 67, 185-189.	0.3	3
178	Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies. <i>Biomaterials</i> , 2021, 270, 120705.	5.7	45
179	Translating Research for the Radiotheranostics of Nanotargeted 188Re-Liposome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3868.	1.8	4
180	Synthesis and characterization of Zn _{0.4} Co _{0.6} Fe ₂ O ₄ superparamagnetic nanoparticles as a promising agent against proliferation of colorectal cancer cells. <i>Ceramics International</i> , 2021, 47, 19026-19035.	2.3	6
181	A comprehensive analysis of SNPs and CNVs identifies novel markers associated with disease outcomes in colorectal cancer. <i>Molecular Oncology</i> , 2021, 15, 3329-3347.	2.1	9
182	Effect of chemotherapy on effect-site concentration of propofol for loss of consciousness in colorectal cancer patients. <i>Korean Journal of Anesthesiology</i> , 2021, , ,	0.9	5

#	ARTICLE	IF	CITATIONS
183	ctDNA on liquid biopsy for predicting response and prognosis in locally advanced rectal cancer: A systematic review. <i>European Journal of Surgical Oncology</i> , 2022, 48, 218-227.	0.5	16
184	The Clinical Utility of Bevacizumab. , 2008, , 375-385.		2
185	Gene Signatures in Colorectal Cancer. , 2012, , 115-136.		2
186	Physical Activity and Gastrointestinal Cancer Survivorship. <i>Recent Results in Cancer Research</i> , 2010, 186, 237-253.	1.8	15
187	A case of colon cancer with metachronous metastasis to the stomach. <i>Research</i> , 0, 1, .	0.0	1
188	Tumor Site- and Stage-Specific Associations between Allelic Variants of Glutathione S-Transferase and DNA-Repair Genes and Overall Survival in Colorectal Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy. <i>PLoS ONE</i> , 2013, 8, e69039.	1.1	15
189	Alterations of lymph nodes evaluation after colon cancer resection: patient and tumor heterogeneity should be taken into consideration. <i>Oncotarget</i> , 2016, 7, 62664-62675.	0.8	11
190	Comparison of survival of patients receiving laparoscopic and open radical resection for stage II colon cancer. <i>Radiology and Oncology</i> , 2011, 45, 273-8.	0.6	5
191	Lymphangiogenesis: A new player in cancer progression. <i>World Journal of Gastroenterology</i> , 2010, 16, 4003.	1.4	64
192	Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patient-derived organoids. <i>International Journal of Oncology</i> , 2020, 57, 1307-1318.	1.4	44
193	The Level of TWIST1 expression determines the response of colon cancer cells to mitogen-activated protein kinases inhibitors. <i>Saudi Journal of Gastroenterology</i> , 2018, 24, 37.	0.5	2
194	Clinical value of 18F-FDG PET/CT in assessing suspicious relapse after rectal cancer resection. <i>World Journal of Gastrointestinal Oncology</i> , 2009, 1, 55.	0.8	2
195	Advances in adjuvant systemic therapy for non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 633.	0.9	19
196	Recent Publications on Medications and Pharmacy. <i>Hospital Pharmacy</i> , 2007, 42, 768-773.	0.4	0
197	Poorly Differentiated Colorectal Adenocarcinoma (Methodology). , 2009, , 13-23.		0
198	2-CONSERVATIVE TREATMENT OF RECTAL ADENOCARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY, IS IT ACCEPTABLE?. <i>Basrah Journal of Surgery</i> , 2009, 15, 3-9.	0.0	0
199	Colon Cancer Experimental Therapy. , 2011, , 903-909.		0
200	Tissue-Engineered "Metastases" Treatment of Hepatic Colon Tumors with a Dual Action Autotaxin Inhibitor-Lysophosphatidic Acid Receptor Antagonist. <i>Journal of Cancer Research Updates</i> , 0, , .	0.3	0

#	ARTICLE	IF	CITATIONS
201	CÁNCER DE RECTO; MANEJO QUIRÚRGICO. Revista Médica De La Universidad De Costa Rica, 2013, 7, .	0.0	0
202	Medical Oncology. , 2008, , 528-780.		0
203	The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. International Journal of Oncology, 2008, 33, 579-84.	1.4	16
204	The association between CD166 detection rate and clinicopathologic parameters of patients with colorectal cancer. Caspian Journal of Internal Medicine, 2013, 4, 768-72.	0.1	11
205	The anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibody EpMab-16 exerts antitumor activity in a mouse model of colorectal adenocarcinoma. Oncology Letters, 2020, 20, 383.	0.8	3
206	The anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibody EpMab-16 exerts antitumor activity in a mouse model of colorectal adenocarcinoma. Oncology Letters, 2020, 20, 1-1.	0.8	17
207	Oncotype DX testing does not affect clinical practice in stage IIa colon cancer. Medical Oncology, 2022, 39, 59.	1.2	2
208	A synopsis of modern - day colorectal cancer: Where we stand. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188699.	3.3	11
209	Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage. Frontiers in Oncology, 2021, 11, 772920.	1.3	6
212	Diagnosis and management of Lynch syndrome. Frontline Gastroenterology, 2022, 13, e80-e87.	0.9	9
213	Following a standardised pathway: Healthcare professionals' perspectives on person-centred care within <sc>ERAS</sc> for patients with colorectal cancer. Journal of Clinical Nursing, 0, , .	1.4	0
214	N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis. Molecular Therapy, 2023, 31, 517-534.	3.7	15
216	Synergistic effect of sodium butyrate and oxaliplatin on colorectal cancer. Translational Oncology, 2023, 27, 101598.	1.7	10
217	Comprehensive Analysis of Potential Prognostic Values of ANGPTLs in Colorectal Cancer. Genes, 2022, 13, 2215.	1.0	2
218	Cedrol, a Sesquiterpene Isolated from <i>Juniperus chinensis</i>, Inhibits Human Colorectal Tumor Growth associated through Downregulation of Minichromosome Maintenance Proteins. Journal of Cancer Prevention, 2022, 27, 221-228.	0.8	2
219	Construction and Validation of a Novel Prognosis Model in Colon Cancer Based on Cuproptosis-Related Long Non-Coding RNAs. Journal of Clinical Medicine, 2023, 12, 1528.	1.0	1